At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
Tygacildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Jun 20, 2007·Updated Oct 24, 2012
In Brief
A Phase 2 clinical trial evaluating Tygacil for Bacterial Infections and 4 related conditions. Completed, enrolled 59 participants across 36 sites in 6 countries.
Detailed Summary
To determine the pharmacokinetic profile and to evaluate the safety and tolerability of ascending multiple doses of tigecycline in patients aged 8 to 11 years with selected serious infections; complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI), or community-acquired pneumonia (CAP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Infections, Intra-Abdominal Infection, Pneumonia, Bacterial, Skin Diseases, Bacterial, Skin Diseases, Infectious
CountriesBelgium, Mexico, South Africa, Taiwan, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2007
Enrollment StartDec 2007
Primary CompletionSep 2009
TodayJul 2026
First PostedJun 20, 2007
Enrollment StartDec 1, 2007
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.0 years ago
Interventions
Tygacildrug